OC-26 PROSTATE CANCER: SINGLE FRACTION HDR BOOST – 12.5GY OR 15GY -WITH EXTERNAL BEAM RADIATION. A COMPARISON OF TOXICITY

Conclusions: The results indicate that large doses per fraction of high-dose-rate brachytherapy are feasible and early and late adverse events manageable. The incidence of severe early urinary events is similar in both groups but a higher proportion of patients required catheterization after 19 Gy HDR-BT, although the numbers in this group are small at present. This may reflect greater acute radiation effectsfrom the single dose although many cases are related to haematuria and clot retention. Biochemical control for locally advanced prostate cancer in patients treated with 26 Gy at 2 years is encouraging.